サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1472248

包括的代謝パネル検査市場：検査タイプ別、適応疾患別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Comprehensive Metabolic Panel Testing Market By Test Type, By Disease Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日
ページ情報
英文 266 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
包括的代謝パネル検査市場：検査タイプ別、適応疾患別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年
出版日: 2024年02月01日
発行: Allied Market Research
ページ情報: 英文 266 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

包括的代謝パネル検査市場は、2022年に101億米ドルとなり、2023年から2032年までのCAGRは4.8%を記録し、2032年までには161億米ドルに達すると予測されています。

包括的代謝パネル（CMP）は、血液中の複数の物質を測定する血液検査です。包括的代謝パネル検査では、血液中の糖のレベルを示すグルコース値を測定し、糖尿病の診断や既往症のモニタリングに使用されます。また、CMP検査には、ナトリウム、カリウム、塩化物などの電解質の検査も含まれます。これらの電解質は、体液のバランスを維持し、収縮力などの神経や筋肉の機能を正常に保つために重要です。

Comprehensive Metabolic Panel Testing Market-IMG1

さらに、CMP検査は、個人の血液中の尿素窒素（BUN）とクレアチニンの量を測定することによって腎臓の働きを研究し、腎臓の問題の早期発見に貢献します。例えば、アラニンアミノトランスフェラーゼ（ALT）とアスパラギン酸アミノトランスフェラーゼ（AST）は、どちらも肝臓内の損傷や病気の発生を示すことで、肝臓の健康状態を調べます。全体として、包括的代謝パネルは主要な生理学的プロセスの包括的な概要を提供し、ヘルスケア専門家が様々な病状を診断・管理するのに役立ちます。

包括的代謝パネル検査市場の成長を促進する要因には、診断サービスに対する需要の増加や、CMP検査のような正確でタイムリーな診断ツールを必要とする糖尿病、心血管疾患、脳卒中などの慢性疾患があります。例えば、米国疾病予防管理センター（CDC）によると、2022年までに米国の成人10人のうち6人が糖尿病に罹患します。このように、糖尿病、心血管疾患、腎臓病などの疾患の有病率の増加は、定期的な生検を必要とし、市場の成長を促進します。

加えて、医療意識の高まりとスクリーニング・プログラムは、包括的代謝パネル（CMP）検査の必要性に大きく寄与しています。公衆衛生の取り組みにおいて予防ヘルスケアの重要性が高まるにつれ、定期検診の利点を人々に啓蒙するための重要な要素となっています。このような制度は早期発見と早期介入を促進するため、ヘルスケアに関する積極的な管理習慣が培われ、市場の成長を後押ししています。さらに、予防ヘルスケアへのシフトは、包括的代謝パネル検査市場の成長を促進する重要な要因です。ヘルスケアの進化に伴い、迅速なヘルスケアと早期診断が重視されるようになり、この動向は個人に定期的な健康診断の導入を促し、より深刻な状況が顕在化する前に潜在的な健康リスクを特定することを優先させ、市場成長を促進しています。

さらに、高齢者人口の増加により、ヘルスケアと診断検査の必要性が高まっています。高齢者は糖尿病、心臓病、腎臓病などの慢性疾患を発症する可能性が高いため、健康全般をモニターし、慢性疾患を管理するために、包括的な代謝プログラムを用いたより頻繁な健康診断が必要となることが多いです。包括的な生化学的情報を提供する包括的な組織検査は、高齢者の健康維持とこれらの疾患の管理において重要です。

しかし、個人とヘルスケア提供者の双方の認識不足が、包括的代謝パネル検査分野の拡大に大きな障害となっています。さらに、ヘルスケア事業における厳しい規制要件やコンプライアンス基準は、検査室や診断サービスプロバイダーに困難をもたらし、市場成長の妨げとなっています。対照的に、ポイントオブケア検査の拡大により、現場での迅速な結果が可能になり、ヘルスケア専門家に利便性と迅速な意思決定を提供しています。特に分散化したヘルスケア環境において、ポイントオブケアソリューションの一環としてCMP検査を市場開拓し採用することは、市場成長にとって有利な機会を提供します。

包括的代謝パネル検査市場は、検査タイプ、適応疾患、エンドユーザー、地域によって区分されます。検査タイプ別では、市場はタンパク質、電解質、腎臓検査、肝臓検査、その他に分類されます。適応疾患別では、腎臓病、肝臓病、糖尿病、その他に分類されます。エンドユーザー別では、病院、診断ラボ、その他に分類されます。

利害関係者にとっての主なメリット

  • 当レポートは、2022年から2032年までの包括的代謝パネル検査市場分析の市場セグメント、現在の動向、推定・力学の定量分析を提供し、優勢な包括的代謝パネル検査市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
  • 包括的代謝パネル検査市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
  • 本レポートには、地域別および世界の包括的代謝パネル検査市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートのカスタマイズが可能です（追加費用とタイムラインに関しましては販売担当へご連絡ください）

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別追加分析 - 市場規模と予測
  • クリスクロスセグメント分析 - 市場規模と予測
  • 企業プロファイルの拡張リスト
  • 主要プレーヤーの詳細（所在地、連絡先、サプライヤー / ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 包括的代謝パネル検査市場：検査タイプ別

  • 概要
  • タンパク質
  • 電解質
  • 腎臓検査
  • 肝臓検査
  • その他

第5章 包括的代謝パネル検査市場：適応疾患別

  • 概要
  • 腎臓疾患
  • 肝臓疾患
  • 糖尿病
  • その他

第6章 包括的代謝パネル検査市場：エンドユーザー別

  • 概要
  • 病院
  • 診断研究所
  • その他

第7章 包括的代謝パネル検査市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • コロンビア
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東・アフリカ
    • GCC
    • 南アフリカ
    • 北アフリカ
    • その他中東・アフリカ

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • Quest Diagnostics
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Walk-In Lab, LLC.
  • Applied InGENuity Diagnostics
  • Scion Lab Services, LLC
  • Baptist Health
  • My Care Labs
  • Blueprint Genetics
図表

LIST OF TABLES

  • TABLE 01. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 02. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 08. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 41. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 82. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 83. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 85. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 91. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 92. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 94. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 95. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 96. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 99. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 101. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. QUEST DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 107. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 108. QUEST DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 109. QUEST DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 110. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 111. QUEST DIAGNOSTICS: KEY STRATERGIES
  • TABLE 112. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
  • TABLE 113. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 114. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
  • TABLE 115. LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE SEGMENTS
  • TABLE 116. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 117. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 118. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 119. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 120. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 121. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 123. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 124. ARUP LABORATORIES: KEY EXECUTIVES
  • TABLE 125. ARUP LABORATORIES: COMPANY SNAPSHOT
  • TABLE 126. ARUP LABORATORIES: PRODUCT SEGMENTS
  • TABLE 127. ARUP LABORATORIES: SERVICE SEGMENTS
  • TABLE 128. ARUP LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 129. ARUP LABORATORIES: KEY STRATERGIES
  • TABLE 130. WALK-IN LAB, LLC.: KEY EXECUTIVES
  • TABLE 131. WALK-IN LAB, LLC.: COMPANY SNAPSHOT
  • TABLE 132. WALK-IN LAB, LLC.: PRODUCT SEGMENTS
  • TABLE 133. WALK-IN LAB, LLC.: SERVICE SEGMENTS
  • TABLE 134. WALK-IN LAB, LLC.: PRODUCT PORTFOLIO
  • TABLE 135. WALK-IN LAB, LLC.: KEY STRATERGIES
  • TABLE 136. APPLIED INGENUITY DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 137. APPLIED INGENUITY DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 138. APPLIED INGENUITY DIAGNOSTICS: PRODUCT SEGMENTS
  • TABLE 139. APPLIED INGENUITY DIAGNOSTICS: SERVICE SEGMENTS
  • TABLE 140. APPLIED INGENUITY DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 141. APPLIED INGENUITY DIAGNOSTICS: KEY STRATERGIES
  • TABLE 142. SCION LAB SERVICES, LLC: KEY EXECUTIVES
  • TABLE 143. SCION LAB SERVICES, LLC: COMPANY SNAPSHOT
  • TABLE 144. SCION LAB SERVICES, LLC: PRODUCT SEGMENTS
  • TABLE 145. SCION LAB SERVICES, LLC: SERVICE SEGMENTS
  • TABLE 146. SCION LAB SERVICES, LLC: PRODUCT PORTFOLIO
  • TABLE 147. SCION LAB SERVICES, LLC: KEY STRATERGIES
  • TABLE 148. BAPTIST HEALTH: KEY EXECUTIVES
  • TABLE 149. BAPTIST HEALTH: COMPANY SNAPSHOT
  • TABLE 150. BAPTIST HEALTH: PRODUCT SEGMENTS
  • TABLE 151. BAPTIST HEALTH: SERVICE SEGMENTS
  • TABLE 152. BAPTIST HEALTH: PRODUCT PORTFOLIO
  • TABLE 153. BAPTIST HEALTH: KEY STRATERGIES
  • TABLE 154. MY CARE LABS: KEY EXECUTIVES
  • TABLE 155. MY CARE LABS: COMPANY SNAPSHOT
  • TABLE 156. MY CARE LABS: PRODUCT SEGMENTS
  • TABLE 157. MY CARE LABS: SERVICE SEGMENTS
  • TABLE 158. MY CARE LABS: PRODUCT PORTFOLIO
  • TABLE 159. MY CARE LABS: KEY STRATERGIES
  • TABLE 160. BLUEPRINT GENETICS: KEY EXECUTIVES
  • TABLE 161. BLUEPRINT GENETICS: COMPANY SNAPSHOT
  • TABLE 162. BLUEPRINT GENETICS: PRODUCT SEGMENTS
  • TABLE 163. BLUEPRINT GENETICS: SERVICE SEGMENTS
  • TABLE 164. BLUEPRINT GENETICS: PRODUCT PORTFOLIO
  • TABLE 165. BLUEPRINT GENETICS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPREHENSIVE METABOLIC PANEL TESTING MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: COMPREHENSIVE METABOLIC PANEL TESTING MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022
目次
Product Code: A269963

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Comprehensive Metabolic Panel Testing Market - IMG1

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Proteins
  • Electrolytes
  • Kidney Tests
  • Liver Tests
  • Others

By Disease Indication

  • Kidney Diseases
  • Liver Diseases
  • Diabtes
  • Others

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Quest Diagnostics
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Walk-In Lab, LLC.
    • Applied InGENuity Diagnostics
    • Scion Lab Services, LLC
    • Baptist Health
    • My Care Labs
    • Blueprint Genetics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Proteins
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Electrolytes
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Kidney Tests
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Liver Tests
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Kidney Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Liver Diseases
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Diabetes
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Test Type
    • 7.2.3. Market size and forecast, by Disease Indication
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Test Type
      • 7.2.5.1.2. Market size and forecast, by Disease Indication
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Test Type
      • 7.2.5.2.2. Market size and forecast, by Disease Indication
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Test Type
      • 7.2.5.3.2. Market size and forecast, by Disease Indication
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Test Type
    • 7.3.3. Market size and forecast, by Disease Indication
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Test Type
      • 7.3.5.1.2. Market size and forecast, by Disease Indication
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Test Type
      • 7.3.5.2.2. Market size and forecast, by Disease Indication
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Test Type
      • 7.3.5.3.2. Market size and forecast, by Disease Indication
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Test Type
      • 7.3.5.4.2. Market size and forecast, by Disease Indication
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Test Type
      • 7.3.5.5.2. Market size and forecast, by Disease Indication
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Test Type
      • 7.3.5.6.2. Market size and forecast, by Disease Indication
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Test Type
    • 7.4.3. Market size and forecast, by Disease Indication
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Test Type
      • 7.4.5.1.2. Market size and forecast, by Disease Indication
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Test Type
      • 7.4.5.2.2. Market size and forecast, by Disease Indication
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Test Type
      • 7.4.5.3.2. Market size and forecast, by Disease Indication
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Test Type
      • 7.4.5.4.2. Market size and forecast, by Disease Indication
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Test Type
      • 7.4.5.5.2. Market size and forecast, by Disease Indication
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Test Type
      • 7.4.5.6.2. Market size and forecast, by Disease Indication
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Test Type
    • 7.5.3. Market size and forecast, by Disease Indication
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Test Type
      • 7.5.5.1.2. Market size and forecast, by Disease Indication
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Test Type
      • 7.5.5.2.2. Market size and forecast, by Disease Indication
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Test Type
      • 7.5.5.3.2. Market size and forecast, by Disease Indication
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Test Type
      • 7.5.5.4.2. Market size and forecast, by Disease Indication
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Test Type
    • 7.6.3. Market size and forecast, by Disease Indication
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Test Type
      • 7.6.5.1.2. Market size and forecast, by Disease Indication
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Test Type
      • 7.6.5.2.2. Market size and forecast, by Disease Indication
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Test Type
      • 7.6.5.3.2. Market size and forecast, by Disease Indication
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Test Type
      • 7.6.5.4.2. Market size and forecast, by Disease Indication
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Quest Diagnostics
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Laboratory Corporation of America Holdings
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. ARUP Laboratories
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Walk-In Lab, LLC.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Applied InGENuity Diagnostics
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Scion Lab Services, LLC
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Baptist Health
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. My Care Labs
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Blueprint Genetics
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments